Currently, in the same setting, a randomized, double-blind, placebo-controlled phase III trial (RENAVIV) is investigating the combination of pazopanib plus the potent oral pan-HDAC inhibitor abexinostat versus pazopanib alone in patients with advanced ccRCC and without prior exposure to anti-angiogenic TKIs (NCT03592472) [44]. Here, HDAC9 is linked to nonpapillary renal cell carcinoma.